Lifemel Honey to Reduce Leucopenia During Chemotherapy

Phase 2

• Conditions: Breast Cancer

• Registration Number: NCT00243165
• Lead Sponsor: Rambam Health Care Campus

Brief Summary

This study will include 60 patients with early breast cancer referred to receive adjuvant chemotherapy with AC ( adriamycin- cyclophosphamide) or CAF ( adriamycin- cyclophosphamide- 5- fluorouracil ) combinations. These patients will receive every day one spoon of Lifemel honey or regular honey ( double blind)- during the adjuvant chemotherapy .Every week a WBC count will be performed in order to record the influence of Lifemel on myelotoxicity.

Detailed Description

Not available

Study Timeline

• Status Verified: 2005-10
• Study First Submitted: 2005-10-20
• Study First Submitted QC: 2005-10-20
• Study First Posted: 2005-10-21
• Study Start: 2005-11
• Last Update Submitted: 2009-12-04
• Last Update Posted: 2009-12-07

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: Female
• Target Recruitment: 60

Inclusion Criteria

• breast cancer patient treated with adjuvant chemotherapy
• PS = 2 or less

Exclusion Criteria

• none

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Prevention of myelotoxicity-every week during chemotherapy.